Zacks Investment Research News Agency
5 hours ago•Zacks Investment Research
Stocks Medium Importance Neutral
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.

Related Symbols 1
ACRS ACRS
Source: Zacks Investment Research
Visit Source
0 0 0
Comment

Comments

0
No comments yet
Be the first person to comment on this news item.